Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 16 | 2023 | 346 | 2.590 |
Why?
|
| Hydroxyurea | 9 | 2016 | 87 | 1.590 |
Why?
|
| Antisickling Agents | 5 | 2013 | 18 | 0.990 |
Why?
|
| Iron | 5 | 2009 | 303 | 0.740 |
Why?
|
| Fetal Hemoglobin | 4 | 2016 | 28 | 0.700 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2024 | 2858 | 0.610 |
Why?
|
| Stroke | 3 | 2023 | 1078 | 0.530 |
Why?
|
| Phosphoglycerate Kinase | 2 | 2006 | 7 | 0.500 |
Why?
|
| Anemia, Hemolytic | 2 | 2006 | 32 | 0.490 |
Why?
|
| Exome | 3 | 2017 | 1085 | 0.480 |
Why?
|
| Mutation, Missense | 3 | 2020 | 940 | 0.480 |
Why?
|
| Genetic Variation | 5 | 2024 | 1594 | 0.420 |
Why?
|
| DNA Damage | 5 | 2024 | 517 | 0.410 |
Why?
|
| Pyrophosphatases | 1 | 2013 | 22 | 0.400 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2013 | 69 | 0.400 |
Why?
|
| Erythrocytes | 2 | 2021 | 232 | 0.400 |
Why?
|
| Antimicrobial Cationic Peptides | 3 | 2007 | 39 | 0.390 |
Why?
|
| Membrane Proteins | 2 | 2013 | 1605 | 0.380 |
Why?
|
| Iron Overload | 2 | 2009 | 16 | 0.380 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2024 | 54 | 0.370 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2010 | 7 | 0.330 |
Why?
|
| Inflammasomes | 2 | 2022 | 170 | 0.320 |
Why?
|
| Promoter Regions, Genetic | 4 | 2013 | 1420 | 0.310 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 1825 | 0.310 |
Why?
|
| Genetic Markers | 1 | 2011 | 622 | 0.310 |
Why?
|
| beta-Thalassemia | 1 | 2009 | 30 | 0.310 |
Why?
|
| Haplotypes | 3 | 2013 | 545 | 0.300 |
Why?
|
| Caspase 2 | 2 | 2024 | 28 | 0.300 |
Why?
|
| Nuclear Proteins | 4 | 2024 | 1338 | 0.290 |
Why?
|
| Intestinal Absorption | 2 | 2007 | 193 | 0.290 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 137 | 0.280 |
Why?
|
| Mutation | 5 | 2024 | 6314 | 0.270 |
Why?
|
| Hemochromatosis | 1 | 2007 | 38 | 0.260 |
Why?
|
| Pyridoxal Kinase | 1 | 2006 | 2 | 0.250 |
Why?
|
| Amidohydrolases | 1 | 2006 | 23 | 0.250 |
Why?
|
| Liver | 3 | 2009 | 1852 | 0.250 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2024 | 3362 | 0.250 |
Why?
|
| Genomics | 1 | 2014 | 1670 | 0.250 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2007 | 107 | 0.250 |
Why?
|
| Receptors, Transferrin | 1 | 2006 | 14 | 0.250 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2006 | 79 | 0.240 |
Why?
|
| Gene Expression Regulation | 2 | 2012 | 2632 | 0.230 |
Why?
|
| Child, Preschool | 13 | 2024 | 14917 | 0.230 |
Why?
|
| Hemolysis | 3 | 2022 | 114 | 0.230 |
Why?
|
| Child | 16 | 2024 | 25900 | 0.230 |
Why?
|
| Genome-Wide Association Study | 3 | 2024 | 1840 | 0.220 |
Why?
|
| UDPglucose-Hexose-1-Phosphate Uridylyltransferase | 1 | 2004 | 3 | 0.220 |
Why?
|
| Alcohol Drinking | 1 | 2007 | 361 | 0.210 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 359 | 0.210 |
Why?
|
| Antigens, CD | 1 | 2006 | 441 | 0.210 |
Why?
|
| Wnt Signaling Pathway | 1 | 2024 | 205 | 0.200 |
Why?
|
| Adolescent | 13 | 2024 | 20607 | 0.200 |
Why?
|
| Apoptosis | 2 | 2024 | 1928 | 0.180 |
Why?
|
| Substance-Related Disorders | 1 | 2006 | 492 | 0.180 |
Why?
|
| Nervous System Diseases | 1 | 2006 | 412 | 0.180 |
Why?
|
| Caspases, Initiator | 1 | 2021 | 6 | 0.180 |
Why?
|
| Humans | 32 | 2024 | 133242 | 0.170 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2021 | 29 | 0.170 |
Why?
|
| Cohort Studies | 4 | 2020 | 5176 | 0.170 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2020 | 12 | 0.170 |
Why?
|
| Carrier Proteins | 3 | 2016 | 1071 | 0.170 |
Why?
|
| Inflammation | 3 | 2022 | 1546 | 0.170 |
Why?
|
| Caspases | 1 | 2021 | 166 | 0.170 |
Why?
|
| Brain Ischemia | 1 | 2023 | 278 | 0.160 |
Why?
|
| Blood Group Antigens | 1 | 2020 | 77 | 0.160 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2019 | 19 | 0.160 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2019 | 10 | 0.160 |
Why?
|
| Blood Cells | 1 | 2019 | 55 | 0.160 |
Why?
|
| Cell Proliferation | 2 | 2024 | 2558 | 0.150 |
Why?
|
| Drug Resistance | 1 | 2020 | 262 | 0.150 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 235 | 0.150 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 141 | 0.150 |
Why?
|
| Endothelial Cells | 1 | 2022 | 536 | 0.150 |
Why?
|
| Hepcidins | 3 | 2007 | 27 | 0.150 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 277 | 0.150 |
Why?
|
| Chronic Disease | 3 | 2009 | 1237 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 571 | 0.140 |
Why?
|
| Gene Frequency | 3 | 2020 | 750 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 342 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 1059 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 2 | 2014 | 175 | 0.130 |
Why?
|
| Macrophages | 1 | 2021 | 698 | 0.130 |
Why?
|
| Metalloendopeptidases | 1 | 2016 | 103 | 0.130 |
Why?
|
| Genotype | 4 | 2024 | 2718 | 0.130 |
Why?
|
| Albuminuria | 1 | 2016 | 113 | 0.120 |
Why?
|
| Polymorphism, Genetic | 2 | 2013 | 810 | 0.120 |
Why?
|
| Male | 15 | 2024 | 65435 | 0.120 |
Why?
|
| Transcriptome | 1 | 2022 | 1134 | 0.120 |
Why?
|
| Glucosephosphate Dehydrogenase | 2 | 2013 | 16 | 0.120 |
Why?
|
| beta-Globins | 2 | 2013 | 9 | 0.120 |
Why?
|
| Thrombosis | 1 | 2019 | 543 | 0.110 |
Why?
|
| Open Reading Frames | 1 | 2014 | 220 | 0.110 |
Why?
|
| Repressor Proteins | 3 | 2016 | 870 | 0.110 |
Why?
|
| Female | 14 | 2024 | 71474 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1704 | 0.100 |
Why?
|
| Risk Factors | 4 | 2016 | 10938 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 1583 | 0.100 |
Why?
|
| Heme | 2 | 2022 | 53 | 0.090 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2011 | 8 | 0.090 |
Why?
|
| Interleukin-1beta | 2 | 2022 | 166 | 0.090 |
Why?
|
| RNA | 2 | 2022 | 605 | 0.090 |
Why?
|
| Mice | 6 | 2024 | 18888 | 0.080 |
Why?
|
| Micronucleus Tests | 1 | 2010 | 3 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 198 | 0.080 |
Why?
|
| Infant | 5 | 2024 | 13264 | 0.080 |
Why?
|
| Time | 1 | 2010 | 99 | 0.080 |
Why?
|
| Brazil | 2 | 2023 | 138 | 0.080 |
Why?
|
| Transcription Factors | 3 | 2016 | 2716 | 0.080 |
Why?
|
| DNA Mutational Analysis | 2 | 2011 | 834 | 0.070 |
Why?
|
| Cytoplasm | 1 | 2009 | 300 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2012 | 4848 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2014 | 2144 | 0.070 |
Why?
|
| Phenotype | 2 | 2016 | 4572 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2011 | 591 | 0.070 |
Why?
|
| Adult | 7 | 2023 | 31746 | 0.070 |
Why?
|
| Alleles | 3 | 2020 | 1693 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2009 | 265 | 0.070 |
Why?
|
| Luminescence | 1 | 2007 | 18 | 0.070 |
Why?
|
| Linear Models | 1 | 2009 | 718 | 0.070 |
Why?
|
| Response Elements | 1 | 2007 | 107 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2016 | 6579 | 0.070 |
Why?
|
| Mice, Inbred AKR | 1 | 2007 | 14 | 0.070 |
Why?
|
| Hemochromatosis Protein | 1 | 2007 | 23 | 0.070 |
Why?
|
| Endotoxins | 1 | 2007 | 49 | 0.070 |
Why?
|
| Luciferases | 1 | 2007 | 134 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2007 | 4818 | 0.060 |
Why?
|
| Animals | 6 | 2024 | 35916 | 0.060 |
Why?
|
| Spain | 1 | 2006 | 65 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2006 | 150 | 0.060 |
Why?
|
| Solubility | 1 | 2006 | 137 | 0.060 |
Why?
|
| Linkage Disequilibrium | 1 | 2006 | 317 | 0.060 |
Why?
|
| Migraine Disorders | 1 | 2006 | 66 | 0.060 |
Why?
|
| Retinal Degeneration | 1 | 2006 | 103 | 0.060 |
Why?
|
| Protein Folding | 1 | 2006 | 222 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 378 | 0.060 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2004 | 6 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1904 | 0.060 |
Why?
|
| Galactosemias | 1 | 2004 | 15 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 316 | 0.060 |
Why?
|
| Gene Expression | 1 | 2009 | 1598 | 0.060 |
Why?
|
| Cell Self Renewal | 1 | 2024 | 50 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2021 | 3124 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 778 | 0.050 |
Why?
|
| Alu Elements | 1 | 2004 | 67 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2006 | 786 | 0.050 |
Why?
|
| ADAMTS Proteins | 1 | 2023 | 9 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 355 | 0.050 |
Why?
|
| Microfluidics | 1 | 2022 | 28 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2009 | 3978 | 0.050 |
Why?
|
| Base Sequence | 1 | 2006 | 3147 | 0.050 |
Why?
|
| Alarmins | 1 | 2021 | 5 | 0.040 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2022 | 128 | 0.040 |
Why?
|
| Developmental Disabilities | 1 | 2006 | 748 | 0.040 |
Why?
|
| DNA | 1 | 2006 | 1671 | 0.040 |
Why?
|
| Cell Death | 1 | 2021 | 248 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 141 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 420 | 0.040 |
Why?
|
| Syndrome | 2 | 2017 | 1173 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2006 | 2866 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 625 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2014 | 13072 | 0.040 |
Why?
|
| Intellectual Disability | 1 | 2006 | 1094 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 897 | 0.040 |
Why?
|
| Exons | 1 | 2020 | 823 | 0.030 |
Why?
|
| Apolipoprotein L1 | 1 | 2016 | 12 | 0.030 |
Why?
|
| Duffy Blood-Group System | 1 | 2016 | 9 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2024 | 2026 | 0.030 |
Why?
|
| Apolipoproteins | 1 | 2016 | 72 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3781 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 824 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 249 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2016 | 117 | 0.030 |
Why?
|
| Young Adult | 2 | 2023 | 9976 | 0.030 |
Why?
|
| Leukocytes | 1 | 2016 | 216 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2019 | 805 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 494 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 369 | 0.030 |
Why?
|
| Oncogene Proteins v-myb | 1 | 2013 | 4 | 0.030 |
Why?
|
| alpha-Thalassemia | 1 | 2013 | 13 | 0.030 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2013 | 49 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 541 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1728 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 586 | 0.030 |
Why?
|
| Middle Aged | 3 | 2023 | 29026 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2013 | 62 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2006 | 8635 | 0.020 |
Why?
|
| Bilirubin | 1 | 2013 | 131 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 955 | 0.020 |
Why?
|
| V(D)J Recombination | 1 | 2011 | 7 | 0.020 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2011 | 13 | 0.020 |
Why?
|
| CRADD Signaling Adaptor Protein | 1 | 2009 | 4 | 0.020 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2009 | 6 | 0.020 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2009 | 12 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2009 | 11 | 0.020 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2009 | 21 | 0.020 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2009 | 39 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 746 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2009 | 167 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2009 | 147 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 319 | 0.020 |
Why?
|
| Biosensing Techniques | 1 | 2009 | 69 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2009 | 152 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 630 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2009 | 366 | 0.020 |
Why?
|
| DNA Repair | 1 | 2011 | 573 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2009 | 838 | 0.020 |
Why?
|
| RNA Interference | 1 | 2009 | 540 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1653 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1312 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 1083 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 798 | 0.020 |
Why?
|
| Ireland | 1 | 2004 | 34 | 0.010 |
Why?
|
| Mitochondria | 1 | 2009 | 752 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 931 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 412 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2021 | 17503 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 3749 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 5449 | 0.010 |
Why?
|
| Prognosis | 1 | 2011 | 5043 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 2503 | 0.010 |
Why?
|
| Diet | 1 | 2007 | 1169 | 0.010 |
Why?
|